AC Immune and Vertex Pharmaceuticals are both medical firms, but which business is better? Based on the strength of dividends, revenue, price, analyst recommendations, valuation, institutional ownership and profitability, we will compare the two firms. Vertex Pharmaceuticals ‘ earnings and valuation have higher income and earnings than AC Immune.
AC Immune trades at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that the two stocks are at present the more affordable. AC Immune has a beta of 0.34, which means that its stock price is 66% less risky than the S&P 500.
Vertex Pharmaceuticals has a ratio of 1.49, which means the stock price is 49% more volatile than the S&P 500. Analyst Recommendations AC Immune already has a $13.50 consensus target price, suggesting a possible 60.91 percent increase. Vertex Pharmaceuticals has a median target price of $221.81, which reflects a potential increase of 0.38%. Equity investors clearly believe that AC Immune is more beneficial than Vertex Pharmaceuticals, given the higher possible potential of AC Immune.
Institutional and Insider Ownership is held by institutional investors at 27.8 percent of AC Immune shares. An institutional investor holds 94.9 percent of Vertex Pharmaceuticals ‘ shares. 0.7% The company owns 0.7% of Vertex Pharmaceuticals ‘ stock.
AC Immune AC Immune logoAC Immune SA, a biopharmaceutical corporation in the commercial stage, identifies, prototypes and produces medical and diagnostic drugs for the prevention, diagnosis, and treatment of protein-related neurodegenerative diseases.
The main drug candidate for the organization is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody in phase III clinical trials for Alzheimer’s disease diagnosis.
Established in 2003, AC Immune SA has its headquarters in Lausanne, Switzerland. Vertex Pharmaceuticals logoVertex Pharmaceuticals Incorporated is involved in the development and promotion of cystic fibrosis treatment therapies.
It is also developing phase III clinical trialsVX-659andVX-445;VX-121, a phase I / II clinical trial cystic fibrosis transmembrane conductance regulator corrector;VX-150, an agent in phase IIb clinical trial for acute pain; CTX001 in phase I / II clinical trial for the treatment of beta-thalassemia and sickle cell disease; and a new drug candidate in phase I / II clinical trial;